Sirio Pharma 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peiqing Li

최고 경영자

CN¥1.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	9.2%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

CEO

Peiqing Li (59 yo)

no data

테뉴어

CN¥1,842,800

보상

Mr. Peiqing Li has been Chairman of the Board and General Manager at Sirio Pharma Company Limited since April 23, 2015 and serves as its Non-Independent Director.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peiqing Li	GM & Chairman of the Board	no data	CN¥1.84m	9.21% CN¥ 590.0m
Qiong Chen	Deputy GM & Director	9.6yrs	CN¥1.62m	7.48% CN¥ 479.4m
Rui Yang	Director	9.6yrs	CN¥120.00k	3.26% CN¥ 208.9m
Zhuangmin Yao	Director	9.6yrs	CN¥1.77m	2.65% CN¥ 170.0m
Guilong Zhu	Independent Director	3.3yrs	CN¥120.00k	데이터 없음
Shiming Hu	Independent Director	3.3yrs	CN¥120.00k	데이터 없음
Jian Gao	Independent Director	3.3yrs	CN¥120.00k	데이터 없음
Meibin Zhang	Non-Employee Supervisor	3.3yrs	데이터 없음	데이터 없음
Shaoqin, Zhu	Supervisor	2.1yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 300791 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Sirio Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 29%

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Now 21% overvalued

Now 21% overvalued

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023)

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.29 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.32 in 1Q 2021)

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥99.91

Sirio Pharma Co., Ltd. announced a financing transaction

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령